What is it about?
Clinically significant synergistic interactions: - penicillins (51%), carbapenems (43%), chloramphenicol (39%) and cephalosporins (33%) in Enterobactaerales; - linezolid (74%), tetracyclines (72%) and daptomycin (56%) in Staphylococcus aureus; - chloramphenicol (53%), aminoglycosides (43%) and cephalosporins (36%) against Pseudomonas aeruginosa; - daptomycin (97%) in Enterococcus spp.; - sulbactam (75%) and penicillins (60%) and in Acinetobacter spp.
Featured Image
Photo by Akshay Chauhan on Unsplash
Why is it important?
It guides clinicians for empirical therapy
Read the Original
This page is a summary of: Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies, Antibiotics, August 2020, MDPI AG,
DOI: 10.3390/antibiotics9080500.
You can read the full text:
Contributors
The following have contributed to this page
